文献速递冠心病

比伐芦定与肝素在急性冠脉综合征侵入性治疗中的比较

Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

MATRIX研究随机纳入7,213例接受侵入性管理的ACS患者,比较比伐芦定与普通肝素(UFH)联用或不联用GPIIb/IIIa抑制剂(GPI)的效果。30天时,三组主要不良心血管事件(MACE)和净不良临床事件(NACE)无显著差异,但比伐芦定显著减少出血,主要为非穿刺部位相关出血,且不受计划GPI使用影响。

要点

  • 比伐芦定与UFH相比,30天MACE和NACE无显著差异。
  • 比伐芦定显著降低出血,尤其是致命性和非穿刺部位出血。
  • 出血获益不受计划GPI使用或UFH术中剂量的影响。

核心结论

  • 在ACS侵入性治疗患者中,比伐芦定与UFH相比未显著降低MACE和NACE,但显著减少出血并发症。

研究设计与样本

  • MATRIX项目随机分配7,213例ACS患者接受比伐芦定或UFH,联用或不联用GPI由术者决定。

主要发现

  • 30天时三组MACE、NACE及死亡、心肌梗死、支架血栓或卒中经调整后无差异。
  • 比伐芦定组较UFH组和UFH+GPI组出血减少,主要为最严重出血包括致命性和非穿刺部位事件,以及输血率和手术穿刺部位修复需求。
  • 比伐芦定组和UFH组补救性GPI使用率分别为4.5%和5.4%(p=0.11)。

临床怎么用

  • 对于接受侵入性管理的ACS患者,比伐芦定可作为减少出血风险的抗凝选择,尤其关注非穿刺部位出血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contrasting evidence exists on the comparative efficacy and safety of bivalirudin and unfractionated heparin (UFH) in relation to the planned use of glycoprotein IIb/IIIa inhibitors (GPIs). OBJECTIVES: This study assessed the efficacy and safety of bivalirudin compared with UFH with or without GPIs in patients with acute coronary syndrome (ACS) who underwent invasive management. METHODS: In the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX) program, 7,213 patients were randomly assigned to receive either bivalirudin or UFH with or without GPIs at discretion of the operator. The 30-day coprimary outcomes were major adverse cardiovascular events (MACEs) (a composite of death, myocardial infarction, or stroke), and net adverse clinical events (NACEs) (a composite of MACEs or major bleeding). RESULTS: Among 3,603 patients assigned to receive UFH, 781 (21.7%) underwent planned treatment with GPI before coronary intervention. Bailout use of GPIs was similar between the bivalirudin and UFH groups (4.5% and 5.4%) (p = 0.11). At 30 days, the 2 coprimary endpoints of MACEs and NACEs, as well as individual endpoints of mortality, myocardial infarction, stent thrombosis or stroke did not differ among the 3 groups after adjustment. Compared with the UFH and UFH+GPI groups, bivalirudin reduced bleeding, mainly the most severe bleeds, including fatal and nonaccess site-related events, as well as transfusion rates and the need for surgical access site repair. These findings were not influenced by the administered intraprocedural dose of UFH and were confirmed at multiple sensitivity analyses, including the randomly allocated access site. CONCLUSIONS: In patients with ACS, the rates of MACEs and NACEs were not significantly lower with bivalirudin than with UFH, irrespective of planned GPI use. However, bivalirudin significantly reduced bleeding complications, mainly those not related to access site, irrespective of planned use of GPIs. (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX [MATRIX]; NCT01433627).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Gargiulo G, Carrara G, Frigoli E, et al. Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. J Am Coll Cardiol. 2018. PMID: 29544607. doi:10.1016/j.jacc.2018.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。